Salesforce has revealed that more than 140 life sciences organizations are now using its Agentforce Life Sciences platform, a direct challenge to Veeva Systems' dominance in pharma cloud software. The announcement came during the Veeva Commercial Summit in Boston, where Veeva CEO Peter Gassner was speaking, underscoring the competitive tension between the two companies.
The platform, which Salesforce calls a 'headless' AI approach, decouples the user interface from backend systems, allowing pharma clients to build custom workflows and integrations. Among the 140-plus adopters are several marquee industry names, though specific client identities were not disclosed. Salesforce positions this as a more flexible alternative to traditional monolithic software.
This push into life sciences represents a significant shift for Salesforce, which has historically focused on customer relationship management across industries. The company aims to capture a slice of the lucrative pharma IT market, currently dominated by Veeva, which counts most top drugmakers among its clients. The rivalry is intensifying as both firms invest heavily in AI and data analytics tailored for drug development and commercial operations.
Market watchers view Salesforce's client count as an early indicator of traction, but note that converting these initial adopters into long-term, large-scale deployments will be key. The life sciences cloud market is estimated at several billion dollars annually, with high switching costs that favor incumbents. Salesforce's 'headless' architecture may appeal to firms seeking more modular, customisable systems.
Some analysts question whether Salesforce can match Veeva's deep domain expertise in regulated environments like clinical trials and pharmacovigilance. Veeva's platform is purpose-built for life sciences compliance, a hurdle that Salesforce must overcome to win over risk-averse pharma buyers.